journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/29150249/accuracy-of-the-cobas-egfr-mutation-assay-in-non-small-cell-lung-cancer-compared-with-three-laboratory-developed-tests
#1
Haruhiko Nakamura, Hirotaka Koizumi, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Hisashi Saji, Masayuki Takagi
BACKGROUND: The reliability of the cobas EGFR assay to detect epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) as an in vitro diagnostic test was compared with 3 laboratory-developed tests (LDTs). MATERIALS AND METHODS: After screening for EGFR mutations using formalin-fixed-paraffin-embedded NSCLC tissue sections using the cobas EGFR assay, 151 samples were further tested with 3 LDTs; the peptide nucleic acid-locked nucleic acid polymerase chain reaction (PCR) clamp, PCR invader, and Cycleave assays...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29129435/etirinotecan-pegol-nktr-102-in-third-line-treatment-of-patients-with-metastatic-or-recurrent-non-small-cell-lung-cancer-results-of-a-phase-ii-study
#2
Charu Aggarwal, Roger B Cohen, Eddy Yu, Wei-Ting Hwang, Joshua M Bauml, Evan Alley, Tracey L Evans, Corey J Langer
BACKGROUND: Third-line treatment options are limited for patients with metastatic non-small-cell lung cancer (NSCLC). Etirinotecan pegol (NKTR-102) is a long-acting topoisomerase-I inhibitor. We conducted a single-arm phase II trial to evaluate its efficacy in third-line treatment. PATIENTS AND METHODS: Patients aged ≥ 18 years with histologically proven NSCLC who had received 2 previous systemic therapy regimens, measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and adequate end-organ function were eligible...
October 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29129434/mutational-landscape-of-ddr2-gene-in-lung-squamous-cell-carcinoma-using-next-generation-sequencing
#3
Charles Ricordel, Alexandra Lespagnol, Francisco Llamas-Gutierrez, Marie de Tayrac, Mallorie Kerjouan, Alice Fievet, Houda Hamdi-Rozé, Amyrat Aliouat, Benoit Desrues, Jean Mosser, Hervé Léna
BACKGROUND: Lung cancer represents the leading cause of cancer-related death worldwide. Despite great advances in lung cancer management with the recent emergence of molecular targeted therapies for non-squamous non-small-cell lung cancer, no dramatic improvements have been achieved in lung squamous cell carcinoma (SCC). Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in this histology. The aim of this study is to describe the DDR2 mutational landscape of lung SCC and investigate the associated clinical factors...
October 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29126779/squamous-cell-carcinoma-transformation-from-egfr-mutated-lung-adenocarcinoma-a-case-report-and-literature-review
#4
Hiroki Izumi, Akira Yamasaki, Yasuto Ueda, Takashi Sumikawa, Hiroyuki Maeta, Shu Nakamoto, Eiji Shimizu
No abstract text is available yet for this article.
October 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29137847/comparison-between-radiological-semantic-features-and-lung-rads-in-predicting-malignancy-of-screen-detected-lung-nodules-in-the-national-lung-screening-trial
#5
Qian Li, Yoganand Balagurunathan, Ying Liu, Jin Qi, Matthew B Schabath, Zhaoxiang Ye, Robert J Gillies
RATIONALE: Lung computed tomography (CT) Screening Reporting and Data System (lung-RADS) has standardized follow-up and management decisions in lung cancer screening. To date, little is known how lung-RADS classification compares with radiological semantic features in risk prediction and diagnostic discrimination. OBJECTIVES: To compare the performance of radiological semantic features and lung-RADS in predicting nodule malignancy in lung cancer screening. METHODS: We used data and low-dose CT (LDCT) images from the National Lung Screening Trial (NLST)...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29133121/analysis-of-early-death-in-japanese-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#6
Takako Inoue, Motohiro Tamiya, Akihiro Tamiya, Kenji Nakahama, Yoshihiko Taniguchi, Takayuki Shiroyama, Shin-Ichi Isa, Kazumi Nishino, Toru Kumagai, Kei Kunimasa, Madoka Kimura, Hidekazu Suzuki, Tomonori Hirashima, Shinji Atagi, Fumio Imamura
BACKGROUND: The increased risk for early death owing to anti-programmed cell death 1 inhibitors is a major disadvantage that requires special management. We evaluated the frequency, causes, and risk factors of early death during nivolumab treatment for non-small cell lung cancer (NSCLC) in a Japanese clinical setting. PATIENTS AND METHODS: The medical records of patients with NSCLC who started receiving nivolumab between December 17, 2015 and July 31, 2016 in 3 Japanese institutes were collected...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29103883/effect-of-brain-metastasis-on-patient-reported-outcomes-in-advanced-nsclc-treated-in-real-world-community-oncology-settings
#7
Mark S Walker, William Wong, Arliene Ravelo, Paul J E Miller, Lee S Schwartzberg
INTRODUCTION: Health-related quality of life (HRQOL) in advanced non-small-cell lung cancer (NSCLC) might be affected by the presence of brain metastasis (BM). We report findings from a prospective observational study that examined HRQOL in patients newly diagnosed with advanced NSCLC, with or without baseline BM, through 1 year of follow-up. PATIENTS AND METHODS: Patients starting first-line treatment of stage IIIB/IV NSCLC were prospectively enrolled and consented at 34 US-based community oncology practices...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29017827/subjective-global-assessment-sga-score-could-be-a-predictive-factor-for-radiation-pneumonitis-in-lung-cancer-patients-with-normal-pulmonary-function-treated-by-intensity-modulated-radiation-therapy-and-concurrent-chemotherapy
#8
Li Ma, WenFeng Ye, QiWen Li, Bin Wang, GuangYu Luo, ZhaoLin Chen, SuPing Guo, Bo Qiu, Hui Liu
INTRODUCTION: To investigate the relationship between malnutrition and the severity of radiation pneumonitis (RP) in patients with lung cancer with normal baseline pulmonary function and lungs' V20 < 35% treated by intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. MATERIALS AND METHODS: A total of 150 patients with lung cancer who received definitive IMRT (≥ 60 Gy) and concurrent chemotherapy were enrolled. In the condition of normal baseline pulmonary function and strict constraints of the irradiation dose to normal lung tissues, we recorded Eastern Cooperative Oncology Group score; concurrent chemotherapy; clinical stage; the level of albumin (ALB), hemoglobin, and C-reactive protein; Subjective Global Assessment (SGA) scores; radiation esophagitis grade; V20 of lungs; and mean lung dose...
September 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28919190/ros1-rearranged-non-small-cell-lung-cancers-with-concomitant-oncogenic-driver-alterations-about-some-rare-therapeutic-dilemmas
#9
LETTER
Laetitia Lambros, Briac Guibourg, Arnaud Uguen
No abstract text is available yet for this article.
September 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28941961/survival-impact-of-cardiac-dose-following-lung-stereotactic-body-radiotherapy
#10
Olive Y Wong, Vivian Yau, Julie Kang, Daniel Glick, Patricia Lindsay, Lisa W Le, Alexander Sun, Andrea Bezjak, B C John Cho, Andrew Hope, Meredith Giuliani
INTRODUCTION: The purpose of this study was to determine the impact of radiation dose to substructures of the heart in lung stereotactic body radiotherapy (SBRT) patients on non-cancer-related deaths. METHODS: Patients treated with lung SBRT at a single institution from 2005 to 2013 were included. The heart and its substructures were contoured, and dose was calculated including mean, max, and max 10 cc dose. Clinical variables including stage, histology, age, gender, Charlson comorbidity index (CCI), preexisting cardiac disease, pulmonary function (forced expiratory volume in 1 second, diffusion capacity), and smoking status were explored for association with non-cancer-related deaths in univariable (UVA) and multivariable (MVA) analyses...
August 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28939097/effect-of-endoscopic-bronchial-ultrasound-on-outcomes-for-stage-i-non-small-cell-lung-cancer-patients-receiving-hypofractionated-radiotherapy
#11
Adil S Akthar, Matthew Koshy, Mark K Ferguson, Septimiu Murgu, D Kyle Hogarth, Daniel W Golden, Philip P Connell, Erik M Davies, Eric Kowalski, Renuka Malik
BACKGROUND: In this study we sought to determine if staging endoscopic bronchial ultrasound (EBUS) improves outcomes in stage I non-small-cell lung cancer (NSCLC) patients who received hypofractionated radiation therapy (HFRT). PATIENTS AND METHODS: Patients with stage I NSCLC treated with HFRT from 2008 to 2015 were retrospectively identified from 3 affiliated institutions. All patients underwent positron emission tomography/computed tomography staging and a subset of patients received pretreatment EBUS...
August 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28958889/prophylactic-cranial-irradiation-for-resectable-small-cell-lung-cancer
#12
REVIEW
Aditya Halthore, Anuj Goenka, Rajiv Sharma, Jonathan P S Knisely
After definitive chemoradiation for small-cell lung cancer (SCLC), prophylactic cranial irradiation (PCI) has been established as standard of care in patients whose tumors respond to treatment. In the modern era, however, a subset of patients might receive upfront resection for SCLC, yet the role of PCI in these patients has not been elucidated. In this review, we examine the literature to better define the role of PCI in this subset of patients. For patients with ≥ T2 disease, incomplete resection, or those not receiving adjuvant chemotherapy, PCI is expected to offer a clinical benefit...
August 26, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28669849/programmed-death-ligand-1-expression-in-paired-non-small-cell-lung-cancer-tumor-samples
#13
Jong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, Yu Feng, Tae-Eun Kim, Heyjoo Choi, Jeanette Baehr Georgsen, Marisa Dolled-Filhart, Kenneth Emancipator, Peter Meldgaard, Jong-Mu Sun, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Wei Zhou, Henrik Hager, Jhingook Kim
BACKGROUND: Programmed death ligand 1 (PD-L1) expression may predict response to anti-programmed death 1 (anti-PD-1) or anti-PD-L1 treatment. There is limited information on changes in PD-L1 expression over time in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Eligible patients with NSCLC who received surgery or underwent biopsy at Samsung Medical Center, Seoul, Republic of Korea, and Aarhus University Hospital, Aarhus, Denmark, between February 2004 and April 2012 were included...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28648531/attitudes-about-lung-cancer-screening-primary-care-providers-versus-specialists
#14
Sritha Rajupet, Dhvani Doshi, Juan P Wisnivesky, Jenny J Lin
BACKGROUND: On the basis of the results of the National Lung Screening Trial, the US Preventive Services Task Force now recommends yearly low-dose computed tomography (LDCT) for lung cancer screening among high-risk individuals. There is limited information regarding physician attitudes toward LDCT screening and whether these vary according to provider specialty. MATERIALS AND METHODS: Primary care providers (PCPs) and specialists were surveyed about their knowledge and attitudes toward lung cancer screening and likelihood to order an LDCT screening...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28623122/a-randomized-phase-ii-study-comparing-nivolumab-with-carboplatin-pemetrexed-for-patients-with-egfr-mutation-positive-nonsquamous-non-small-cell-lung-cancer-who-acquire-resistance-to-tyrosine-kinase-inhibitors-not-due-to-a-secondary-t790m-mutation-rationale
#15
Hidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, Tomonobu Fujita, Hiroshige Yoshioka, Daisuke Sakai, Chiyoe Kitagawa, Tateaki Naito, Koji Takeda, Isamu Okamoto, Tetsuya Mitsudomi, Yutaka Kawakami, Kazuto Nishio, Shinichiro Nakamura, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Antibodies to programmed cell death-1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation-positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28623121/radiomics-based-assessment-of-radiation-induced-lung-injury-after-stereotactic-body-radiotherapy
#16
Angel Moran, Megan E Daly, Stephen S F Yip, Tokihiro Yamamoto
BACKGROUND: Over 50% of patients who receive stereotactic body radiotherapy (SBRT) develop radiographic evidence of radiation-induced lung injury. Radiomics is an emerging approach that extracts quantitative features from image data, which may provide greater value and a better understanding of pulmonary toxicity than conventional approaches. We aimed to investigate the potential of computed tomography-based radiomics in characterizing post-SBRT lung injury. METHODS: A total of 48 diagnostic thoracic computed tomography scans (acquired prior to SBRT and at 3, 6, and 9 months post-SBRT) from 14 patients were analyzed...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601388/a-randomized-placebo-controlled-phase-1b-2-study-of-rilotumumab-or-ganitumab-in-combination-with-platinum-based-chemotherapy-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer
#17
Bonnie Glisson, Benjamin Besse, Manuel Cobo Dols, Sarita Dubey, Marco Schupp, Rajul Jain, Yizhou Jiang, Hari Menon, Kristiaan Nackaerts, Sergey Orlov, Luis Paz-Ares, Rodryg Ramlau, Rui Tang, Yilong Zhang, Min Zhu
INTRODUCTION/BACKGROUND: In this randomized, double-blind, placebo-controlled phase 1b/2 study we assessed the efficacy/safety of rilotumumab or ganitumab combined with etoposide and carboplatin or cisplatin as first-line treatment in patients with extensive stage small-cell lung cancer (ES-SCLC). PATIENTS AND METHODS: In the phase 1b study, patients received rilotumumab 15 mg/kg or ganitumab 18 mg/kg with etoposide and carboplatin or cisplatin. In the phase 2 study, patients were randomly assigned 1:1:1 to receive placebo, rilotumumab, or ganitumab with etoposide and carboplatin or cisplatin...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601387/guideline-concordant-care-improves-overall-survival-for-locally-advanced-non-small-cell-lung-carcinoma-patients-a-national-cancer-database-analysis
#18
Hiba Z Ahmed, Yuan Liu, Kelli O'Connell, Maaz Z Ahmed, Richard J Cassidy, Theresa W Gillespie, Pretesh Patel, Rathi N Pillai, Madhusmita Behera, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Walter J Curran, Kristin A Higgins
BACKGROUND: Current evidence-based guideline-concordant care (GCC) for locally advanced non-small-cell lung cancer (NSCLC) patients with good performance status is concurrent chemoradiation. In this study we evaluated factors associated with lack of GCC and its effects on overall survival (OS). PATIENTS AND METHODS: Unresectable stage III NSCLC patients, diagnosed from 2005 to 2013 with a Charlson-Deyo score of 0, were identified from the National Cancer Database...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601386/detection-of-alk-and-kras-mutations-in-circulating-tumor-dna-of-patients-with-advanced-alk-positive-nsclc-with-disease-progression-during-crizotinib-treatment
#19
Paola Bordi, Marcello Tiseo, Eleonora Rofi, Iacopo Petrini, Giuliana Restante, Romano Danesi, Marzia Del Re
BACKGROUND: In patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), disease progression occurs after a median of 9 to 10 months of crizotinib treatment. Several mechanisms of resistance have been identified and include ALK mutations and amplification or the activation of bypassing signaling pathways. Rebiopsy in NSCLC patients represents a critical issue and the analysis of circulating cell-free DNA (cfDNA) has a promising role for the identification of resistance mechanisms...
November 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28596108/association-between-egfr-t790m-status-and-progression-patterns-during-initial-egfr-tki-treatment-in-patients-harboring-egfr-mutation
#20
Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Yoshitaka Inaba, Toyoaki Hida, Yasushi Yatabe
BACKGROUND: Emergence of the T790M point mutation in exon 20 of the epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study was to investigate the association between T790M mutation status and the progression patterns during EGFR-TKI treatment. METHODS: We reviewed 181 patients with advanced non-small-cell lung cancer harboring EGFR mutation, who were evaluated for T790M mutation status after initial EGFR-TKI failure (gefitinib, erlotinib, or afatinib)...
November 2017: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"